CSPC Innovation Pharmaceutical (300765) Q1 2026 earnings summary

Executive summary

• Achieved revenue of ¥664.65 million in Q1 2026, up 40.82% year-over-year, driven by strong growth in biopharmaceuticals and functional ingredients.

• Biopharmaceutical revenue surged 336.96% year-over-year, with key products and out-licensing milestones contributing significantly.

• Net loss attributable to shareholders was ¥93.85 million, a decline of ¥66.95 million from the prior year, impacted by increased R&D, higher holding in Jushi Biotech, and FX losses.

• R&D investment rose 13.64% year-over-year, with multiple clinical milestones achieved.

Financial highlights

• Revenue: ¥664.65 million, up 40.82% year-over-year.

• Net loss attributable to shareholders: ¥93.85 million, compared to ¥26.90 million loss last year.

• Operating cash flow: -¥179.52 million, down 106.82% year-over-year.

• Basic and diluted EPS: -0.0674, down 251.04% year-over-year.

• Total assets: ¥6.21 billion, down 1.06% from year-end 2025.

Outlook and guidance

• Focus remains on core businesses: biopharmaceuticals, functional ingredients, and health foods.

• Continued emphasis on R&D and commercialization of innovative drugs.